Tenderwize
Retour à la recherche

Parenteral Nutrition Combination Solutions

GWQ ServicePlus AG·Düsseldorf, Germany·Deadline May 10, 2027 · 255 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V zu Lösungen zur parenteralen Ernährung Kombinationen (ATC-Code: B05BA10).

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

Postal submission only is indicated, so late or incomplete physical delivery could invalidate participation.

The notice states the buyer believes the arrangement falls outside cartel procurement law due to no selection decision...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Non-exclusive rebate agreements for pharmaceutical products under § 130a(8) SGB V.
  • Product scope: solutions for parenteral nutrition combinations (ATC code B05BA10).
Afficher le résumé complet

This is a German supplies notice for non-exclusive pharmaceutical rebate agreements under § 130a(8) SGB V for parenteral nutrition combinations (ATC B05BA10). The procedure is open, with postal submission only, and the contract is intended to start on 01.09.2025. The notice indicates an access model where interested companies may join on the same terms during the contract term. No contract value is stated. Procurement documents are available on the buyer portal, but only the TED XML notice text was provided for analysis.

Risques

Postal submission only is indicated, so late or incomplete physical delivery could invalidate participation.

The notice states the buyer believes the arrangement falls outside cartel procurement law due to no selection decision...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Signed contract in duplicate is required.
  • Proof of pharmaceutical marketing authorization via extract from the public AMIce database is required.

Administrative

  • Submission is postal only; electronic submission is not allowed.

Acheteur

Localisation

Düsseldorf, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE258895210

Activité

Health

Lots (1)

LOT-0000

Parenteral Nutrition Combination Solutions

Non-exclusive rebate agreement for parenteral nutrition combination products (ATC B05BA10). The lot text indicates an accession model open to all interested companies on equal terms during the contract term, with contract documents and related information available via the buyer portal. This lot information comes from the structured notice and XML notice text.

SuppliesEU fundedElectronic submission

Localisation

DEA11, Germany

Durée

Aug 2025 - Jun 2027

Catégorie

Pharmaceutical products

Date limite

Deadline May 10, 2027

Détails de la procédure

Date de publication
06 Aug 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
519396-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30